Literature DB >> 9420431

Functional analysis of trk proto-oncogene product in medulloblastoma cells.

T Kokunai1, H Sawa, N Tamaki.   

Abstract

MED-L cells with the 75 kd low-affinity nerve growth factor receptor (p75NGFR) and MED-H cells with the proto-oncogene tropomyosin receptor kinase product (p140trk) were isolated selectively from a parent MED-3 cell line derived from cerebellar medulloblastoma by panning, and the interaction of nerve growth factor (NGF) with these cell lines was analyzed. NGF treatment induced neuronal differentiation, growth inhibition, and tyrosine phosphorylation of p140trk in MED-H cells, but not in MED-L cells. Medulloblastoma cells express the functional NGFR, p140trk, which regulates their differentiation and growth.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9420431     DOI: 10.2176/nmc.36.796

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  5 in total

1.  Overcoming of radioresistance in human gliomas by p21WAF1/CIP1 antisense oligonucleotide.

Authors:  T Kokunai; S Urui; H Tomita; N Tamaki
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

Review 2.  The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers.

Authors:  David S Shulman; Steven G DuBois
Journal:  Paediatr Drugs       Date:  2020-04       Impact factor: 3.022

3.  Zhangfei induces the expression of the nerve growth factor receptor, trkA, in medulloblastoma cells and causes their differentiation or apoptosis.

Authors:  Ximena Valderrama; Noreen Rapin; Valerie M K Verge; Vikram Misra
Journal:  J Neurooncol       Date:  2008-08-22       Impact factor: 4.130

4.  Differentiation and growth inhibition of glioma cells induced by transfer of trk A proto-oncogene.

Authors:  T Kokunai; H Iguchi; N Tamaki
Journal:  J Neurooncol       Date:  1999-03       Impact factor: 4.506

5.  Relationship between expression of p21WAF1/CIP1 and radioresistance in human gliomas.

Authors:  T Kokunai; N Tamaki
Journal:  Jpn J Cancer Res       Date:  1999-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.